| 초록 |
Despite the existence of several working vaccines, the pandemic caused by the spreading of SARS-CoV-2 have continued for over a year and number of cases and deaths are still rapidly increasing. Monoclonal antibodies with high target specificities and prolonged circulating serum half-lives have been considered one of the most effective therapeutics to combat against new emerging viruses such as SARS-CoV-2. Albeit significant high sequence similarity between receptor-binding domains of SARS-CoV-1 and SARS-CoV-2, three potent anti-SARS-CoV-1 antibodies (80R, m396, and S230) cannot recognize spike proteins of SARS-CoV-2. Through employing high throughput-directed evolution of SARS-CoV-1 neutralizng antibodies, we could isolate novel antibodies with high specific binding to SARS-CoV-2 RBD successfully. After production of the resulting antibodies in mammalian cells, their binding affinities and specificities for SARS-CoV-2 variants have been characterized, and the results will be presented. |
